Tag:
Shantha Biotechnics
Latest Headlines
Latest Headlines
Shantha gets go-ahead for operational revamp
Sanofi's plan for revamping Shantha Biotech won Indian government approval, clearing the way for it to recapture WHO contracts for its Shan5 vaccine.
Sanofi's Shantha Biotechnics hopes to relaunch vaccine
Sanofi ( $SNY ) subsidiary Shantha Biotechnics has told The Hindu Business Line it plans to relaunch its pentavalent vaccine, Shan5, next year after a new WHO audit. In August 2010, the World Health
Sanofi amps up Indian vax plant with $300M investment
Indian newspapers are abuzz with Sanofi's ( $SNY ) vaccine play in that country. On a tour there, CEO Chris Viehbacher ( photo ) touted Sanofi's $300 million investment in a "state-of-the-art"
Sanofi boosts India presence with $300M vaccine investment
Lured by growing demand in emerging markets, Sanofi ( $SNY ) CEO Chris Viehbacher ( photo ) says his company's Sanofi Pasteur unit plans to open a vaccine manufacturing plant in India--which is slated to
Sanofi's ($SNY) Shantha buyout fails to live up to expectations
Sanofi-Aventis' ( $SNY ) acquisition of Indian vaccine maker Shantha Biotechnics has failed to live up to analyst forecasts, according to Bloomberg. Sanofi announced in July 2009 that it was paying
Health body cancels Shan5 pre-qualification
The World Health Organization has cancelled the pre-qualification to Shantha Biotechnics' combination vaccine Shan5 because of manufacturing defects found in samples produced at a plant in India.
Sanofi nabs control of Indian vaccine firm
Sanofi-Aventis is putting its finger into yet another emerging markets pie. The French drugmaker forged a deal for control of Shantha Biotechnics, an Indian vaccine maker that boasts manufacturing
